Meeting
2012 Genitourinary Cancers Symposium
Urothelial cancer: Impact of gender on stage at diagnosis and survival.
Authors
Jeanne Michelle du Manoir
Department of Medicine, University of Toronto, Toronto, ON, Canada
Jeanne Michelle du Manoir , Suzanne Richter , Srikala S. Sridhar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session D: Penile, Urethral, Urothelial, and Testicular Cancers
Track
Urothelial Carcinoma,Penile, Urethral, and Testicular Cancer
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 316)
DOI
10.1200/jco.2012.30.5_suppl.316
Abstract #
316
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2023 ASCO Genitourinary Cancers Symposium
TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).
First Author: Ignacio Duran
Poster
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Philippe Barthelemy
Poster
2016 ASCO Annual Meeting
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
First Author: Thomas Powles